Clinical trial
Masitinib in Gastro-intestinal Stromal Tumor (GIST) Resistant to Imatinib
The objective is to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib.
| Category | Value |
|---|---|
| Study start date | 2012-01-03 |